Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.46 |
| ▸ | GABRD | O14764 | 3/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.46 |
| ▸ | GABRE | P78334 | 3/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.45 |
| ▸ | TUBB | P07437 | 2/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7696230 | 0.91 | TTR (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8532689 | 0.88 | GPR84 (0.49) | MEN1KMT2A | |
| SCHEMBL10562875 | 0.87 | HDAC3 (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9226278 | 0.87 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8533040 | 0.84 | GPR84 (0.46) | MEN1KMT2A | |
| SCHEMBL8533902 | 0.84 | GPR84 (0.46) | MEN1KMT2A | |
| SCHEMBL8951403 | 0.84 | HDAC3 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8532302 | 0.83 | GPR84 (0.45) | MEN1KMT2A | |
| SCHEMBL3671157 | 0.83 | GPR84 (0.42) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9372304 | 0.82 | ALDH1A1 (0.42) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186300-A1 | Process for the preparation of zafirlukast | FINETECH LABORATORIES LTD. (IL) | 2004-09-23 | — | — | US | claimed |
| WO-2002046153-A2 | PROCESS FOR THE PREPARATION OF ZAFIRLUKAST | FINETECH LABORATORIES LTD. (IL) | 2002-06-13 | — | — | WO | claimed |
| EP-2170825-A2 | SUBSTITUTED INDOLES | Auspex Pharmaceuticals, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090191183-A1 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090149662-A1 | PROCESSES FOR PREPARING ZAFIRLUKAST | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| WO-2009018280-A2 | SUBSTITUTED INDOLES | AUSPEX PHARAMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20040186300-A1 | Process for the preparation of zafirlukast | FINETECH LABORATORIES LTD. (IL) | 2004-09-23 | — | — | US | disclosed |
| US-20040186300-A1 | Process for the preparation of zafirlukast | FINETECH LABORATORIES LTD. (IL) | 2004-09-23 | — | — | US | disclosed |
| WO-2002046153-A3 | PROCESS FOR THE PREPARATION OF ZAFIRLUKAST | FINETECH LAB LTD (IL) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002046153-A2 | PROCESS FOR THE PREPARATION OF ZAFIRLUKAST | FINETECH LABORATORIES LTD. (IL) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046153-A2 | PROCESS FOR THE PREPARATION OF ZAFIRLUKAST | FINETECH LABORATORIES LTD. (IL) | 2002-06-13 | — | — | WO | disclosed |
| US-5179112-A | Leukotriene antagonist as antiallergens and antiinflammatory agents | ICI AMERICAS INC. (US) | 1993-01-12 | — | — | US | disclosed |
| EP-0490649-A1 | A physical form of N-[4-[5-(cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulfonamide, a process for its preparation and pharmaceutical compositions containing it | ZENECA LIMITED (GB) | 1992-06-17 | — | — | EP | disclosed |
| EP-0490648-A1 | Pharmaceutical agents | ZENECA LIMITED (GB) | 1992-06-17 | — | — | EP | disclosed |
| US-5096917-A | Antiallergens; treatment of asthma, hay fever, genetic disorders | CIBA-GEIGY CORPORATION (US) | 1992-03-17 | — | — | US | disclosed |
| EP-0199543-B1 | HETEROCYCLIC AMIDE DERIVATIVES | ICI AMERICAS INC. (US) | 1991-12-04 | — | — | EP | disclosed |
| US-5030643-A | Antiallergens, antiinflammatory agents | ICI AMERICAS INC. (US) | 1991-07-09 | — | — | US | disclosed |
| US-4837235-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | ICI AMERICAS INC. (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0227241-A2 | Medicinal indole and indazole keto sulphone derivatives | ZENECA INC. (US) | 1987-07-01 | — | — | EP | disclosed |
| EP-0199543-A2 | Heterocyclic amide derivatives | ICI AMERICAS INC. (US) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149662-A1 | PROCESSES FOR PREPARING ZAFIRLUKAST | SI, FIP1L1, KHK | GABRP 1857/4885GABRD 2423/4885GABRA1 2126/4885 |
| US-20090191183-A1 | SUBSTITUTED INDOLES | CYSLTR1, LTB4R, LTB4R2 | GABRP 588/4885GABRD 1213/4885GABRA1 660/4885 |
| US-20040186300-A1 | Process for the preparation of zafirlukast | LTC4S, LTB4R, CMA1 | GABRP 502/4885GABRD 723/4885GABRA1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.